/

IPSC

Century Therapeutics, Inc.Closed

1.38−0.06 −4.17%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 1.38 0.00%

Open

1.44

Prev close

1.44

Day range

1.351.44

52-week range

0.43503.04

Volume

544.25K0.89×

Mkt cap

249.88M

P/E ttm

—

Fwd P/E

-3.07

EPS ttm

-0.9300

Div yield

0.00%

Earnings

Aug 12, 2026

From 52w high

−54.61%

Price Chart

Yahoo Finance · delayed

IPSCOct 13, 2026O 1.44H 1.44L 1.35C 1.38−0.06 (−4.17%)Vol 544.20K

SMA 501.87
SMA 2002.09

1Y change +142.53% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

IPSC Century Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +4.55%
1 month: −28.87%
3 months: −35.21%
6 months: −41.77%
Year to date: +38.69%
1 year: +150.91%

Valuation & ownership

Market cap: 249.88M
Enterprise value: 168.84M
P/E (ttm): —
Forward P/E: -3.07
PEG ratio: —
Price / book: 1.07
Price / sales (ttm): —
EV / EBITDA: -1.77
EPS (ttm): -0.9300
EPS (forward): -0.4500
Beta (5y monthly): 1.67
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 181.08M
Float: 101.25M
Short % of float: 16.26%
Short ratio (days): 60.95
Held by insiders: 8.14%
Held by institutions: 87.43%
Avg volume (3m): 610.15K
50-day average: 1.88
200-day average: 2.09
52-week change: +150.91%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 32.2
vs 50-day SMA: −26.06%
vs 200-day SMA: −33.97%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 8.58%
Realised vol (20d, ann.): 79.3%
From 52-week high: −54.61%
From 52-week low: +217.24%

ANR

Analyst Consensus

4 analysts

Consensus

Buy

1.60 on a 1 (strong buy) – 5 (sell) scale

Mean target

4.75

+244.20% implied

Low 2.00Median 4.50High 8.00

Recommendation trend

Now4 / 1 / 0
1m ago4 / 1 / 0

DES

About Century Therapeutics, Inc.

Yahoo Finance profile

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Sector: Healthcare
Industry: Biotechnology
Employees: 78
Headquarters: Philadelphia, PA, United States
Website: centurytx.com
Officers: Dr. Brent Pfeiffenberger M.B.A., Pharm.D. President, CEO & Chairman
Dr. Gregory Russotti Ph.D. Chief Technology & Manufacturing Officer
Dr. Chad A. Cowan Ph.D. Chief Scientific Officer

SEAS

Seasonality · IPSC

2021–2026 · monthly returns

Strongest month Dec +23.10%Weakest month Aug −13.08%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	91.0	22.1	-2.6	1.3	7.0	0.0	-17.6	1.5	-16.6	-19.3			+38.7%
2025	-18.7	-16.8	-30.3	13.9	-2.2	5.5	-2.0	-10.2	1.2	17.1	-6.5	82.6	−1.5%
2024	28.9	-14.3	13.9	-30.4	2.1	-14.1	-12.5	-21.1	-2.8	-32.7	49.6	-41.3	−69.6%
2023	-10.9	-1.3	-23.1	-9.8	1.6	-0.6	-3.5	-18.7	-19.4	-23.5	-10.5	142.3	−35.3%
2022	-17.8	8.2	-10.7	-4.5	-27.7	-3.3	25.8	-0.5	-6.0	6.2	0.0	-51.1	−67.7%
2021							-0.6	-14.9	1.5	-10.7	-15.0	-17.0	−45.9%

INSD

Insider Activity · IPSC

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 13, 2026	Carr DouglasOfficer	Sale at price 1.93 per share.	1.7K	$3.20K
Sep 13, 2026	Russotti GregoryOfficer	Sale at price 1.93 per share.	2.6K	$4.99K
Sep 7, 2026	Carr DouglasOfficer	Sale at price 2.05 per share.	254	$521
Sep 7, 2026	Russotti GregoryChief Technology Officer	Sale at price 2.05 per share.	534	$1.09K
Aug 2, 2026	Carr DouglasOfficer	Sale at price 1.98 per share.	275	$544
Jun 11, 2026	Carr DouglasOfficer	Sale at price 2.23 per share.	1.7K	$3.69K
Jun 11, 2026	Russotti GregoryChief Technology Officer	Sale at price 2.23 per share.	2.6K	$5.77K
Jun 7, 2026	Carr DouglasOfficer	Sale at price 2.11 per share.	249	$526
Jun 7, 2026	Russotti GregoryChief Technology Officer	Sale at price 2.11 per share.	524	$1.11K
May 3, 2026	Carr DouglasOfficer	Sale at price 2.34 per share.	264	$618
Mar 11, 2026	Carr DouglasOfficer	Sale at price 2.55 per share.	7K	$17.95K
Mar 11, 2026	Russotti GregoryChief Technology Officer	Sale at price 2.55 per share.	10.1K	$25.68K
Mar 8, 2026	Carr DouglasOfficer	Sale at price 2.54 per share.	247	$626
Mar 8, 2026	Russotti GregoryChief Technology Officer	Sale at price 2.54 per share.	479	$1.22K
Feb 2, 2026	Carr DouglasOfficer	Sale at price 1.82 per share.	323	$589
Feb 1, 2026	Carr DouglasOfficer	Stock Award(Grant) at price 0.00 per share.	110K	—
Feb 1, 2026	Russotti GregoryChief Technology Officer	Stock Award(Grant) at price 0.00 per share.	135K	—
Feb 1, 2026	Pfeiffenberger BrentChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	475K	—
Feb 1, 2026	Cowan ChadOfficer	Stock Award(Grant) at price 0.00 per share.	135K	—
Dec 21, 2025	Cowan ChadOfficer	Purchase at price 0.85 per share.	58.1K	$49.25K

13F

Investors Holding IPSC

latest 13F filings of 29 followed managers

Investors holding IPSC
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$3.1M	0.00%	1.26M	+39%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

IPSC

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

IPSC

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Century Therapeutics, Inc.

Seasonality · IPSC

Insider Activity · IPSC

Congress Trades · IPSC

Investors Holding IPSC

Investors Holding IPSC

Congress Trades · IPSC

Seasonality · IPSC

Insider Activity · IPSC

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Century Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News